Literature DB >> 7589152

CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins.

B Huard1, P Prigent, M Tournier, D Bruniquel, F Triebel.   

Abstract

We analyzed CD4 major histocompatibility complex (MHC) class II interactions with CD4 and lymphocyte activation gene (LAG)-3 recombinant fusion proteins termed CD4Ig and LAG-3Ig. CD4Ig bound MHC class II molecules expressed on the cell surface only when used in the micromolar range. This weak CD4Ig binding was specific, since it was inhibited by anti-CD4 and anti-MHC class II mAb. LAG-3Ig bound MHC class II molecules with intermediate avidity (Kd = 60 nM at 37 degrees C). Using LAG-3Ig as a competitor in a CD4/MHC class II-dependent cellular adhesion assay, we showed that this recombinant molecule was able to block CD4/MHC class II interaction. In contrast, no inhibition was observed in a CD4/MHC class II-dependent T cell cytotoxicity assay. Together, these results suggest that co-engagement of the TcR with CD4 alters the CD4/MHC class II molecular interaction to become insensitive to LAG-3Ig competition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589152     DOI: 10.1002/eji.1830250949

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  117 in total

1.  Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.

Authors:  Takeo K Maeda; Daisuke Sugiura; Il-Mi Okazaki; Takumi Maruhashi; Taku Okazaki
Journal:  J Biol Chem       Date:  2019-02-13       Impact factor: 5.157

Review 2.  Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Authors:  Angela K B Alme; Beerinder S Karir; Bishoy M Faltas; Charles G Drake
Journal:  Urol Oncol       Date:  2016-02-28       Impact factor: 3.498

3.  LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.

Authors:  Sandrine Buisson; Frédéric Triebel
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

4.  Characterization and functional studies of forkhead box protein 3(-) lymphocyte activation gene 3(+) CD4(+) regulatory T cells induced by mucosal B cells.

Authors:  K-H Chu; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

Authors:  Yongping Zhang; Xingying Zhang; Chen Cheng; Wei Mu; Xiaojuan Liu; Na Li; Xiaofei Wei; Xiang Liu; Changqing Xia; Haoyi Wang
Journal:  Front Med       Date:  2017-06-17       Impact factor: 4.592

Review 6.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

Review 7.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

Review 8.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 9.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.